Theravance Biopharma/$TBPH
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Theravance Biopharma
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Ticker
$TBPH
Sector
Primary listing
Employees
97
Headquarters
Website
TBPH Metrics
BasicAdvanced
$701M
54.41
$0.26
0.01
-
Price and volume
Market cap
$701M
Beta
0.01
52-week high
$15.15
52-week low
$7.90
Average daily volume
414K
Financial strength
Current ratio
6.705
Quick ratio
6.603
Long term debt to equity
15.816
Total debt to equity
20.662
Interest coverage (TTM)
-13.82%
Profitability
EBITDA (TTM)
-34.311
Gross margin (TTM)
47.33%
Net profit margin (TTM)
16.88%
Operating margin (TTM)
-46.16%
Effective tax rate (TTM)
67.49%
Revenue per employee (TTM)
$800,000
Management effectiveness
Return on assets (TTM)
-5.65%
Return on equity (TTM)
6.23%
Valuation
Price to earnings (TTM)
54.405
Price to revenue (TTM)
8.936
Price to book
3.12
Price to tangible book (TTM)
3.12
Price to free cash flow (TTM)
2.818
Free cash flow yield (TTM)
35.48%
Free cash flow per share (TTM)
4.939
Growth
Revenue change (TTM)
24.49%
Earnings per share change (TTM)
-127.83%
3-year revenue growth (CAGR)
13.80%
10-year revenue growth (CAGR)
8.14%
3-year earnings per share growth (CAGR)
-42.70%
10-year earnings per share growth (CAGR)
-27.57%
What the Analysts think about TBPH
Analyst ratings (Buy, Hold, Sell) for Theravance Biopharma stock.
Bulls say / Bears say
Sold remaining interest in Trelegy royalties to GSK for $225 million, boosting cash reserves and keeping the balance sheet debt-free.
YUPELRI net sales rose 6% year-over-year to $58.3 million in Q1 2025, with a 48% jump in hospital channel doses, showing strong commercial momentum.
TRELEGY net sales, as reported by GSK, grew 14% to $854 million in Q1 2025, positioning Theravance to receive a $50 million milestone payment and highlighting the strength of its partnered portfolio.
First-quarter 2025 adjusted net loss widened to $0.17 per share, missing consensus estimates and spotlighting ongoing unprofitability.
The sale of the remaining Trelegy royalty interest ends future high-margin royalty income from a product that generated $3.46 billion in net sales for FY2024, limiting long-term recurring revenue potential.
Top-line data for Ampreloxetine’s pivotal Phase 3 CYPRESS trial won’t be available until Q1 2026, meaning there’s a prolonged period without major pipeline milestones.
Data summarised monthly by Lightyear AI. Last updated on 4 Oct 2025.
TBPH Financial Performance
Revenues and expenses
TBPH Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Theravance Biopharma stock?
Theravance Biopharma (TBPH) has a market cap of $701M as of October 14, 2025.
What is the P/E ratio for Theravance Biopharma stock?
The price to earnings (P/E) ratio for Theravance Biopharma (TBPH) stock is 54.41 as of October 14, 2025.
Does Theravance Biopharma stock pay dividends?
No, Theravance Biopharma (TBPH) stock does not pay dividends to its shareholders as of October 14, 2025.
When is the next Theravance Biopharma dividend payment date?
Theravance Biopharma (TBPH) stock does not pay dividends to its shareholders.
What is the beta indicator for Theravance Biopharma?
Theravance Biopharma (TBPH) has a beta rating of 0.01. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.